UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1299-7
Program Prior Authorization/Notification
Medications *Fasenra® (benralizumab)
*This program applies to the prefilled autoinjector formulation.
P&T Approval Date 10/2019, 4/2020, 4/2021, 11/2021, 11/2022, 7/2023, 7/2024
Effective Date 10/1/2024
1. Background:
Fasenra (benralizumab) is an interleukin-5 receptor alpha-directed cytolytic monoclonal
antibody indicated for the add-on maintenance treatment of patients with severe asthma aged 6
years and older, and with an eosinophilic phenotype.
Fasenra is not used for treatment of other eosinophilic conditions or for relief of acute
bronchospasm or status asthmaticus.
2. Coverage Criteriaa:
A. Asthma
1. Initial Authorization
a. Fasenra will be approved based on one of the following criteria:
(1) All of the following:
(a) Patient has been established on therapy with Fasenra under an active
UnitedHealthcare medical benefit prior authorization for the treatment of
severe asthma
-AND-
(b) Documentation of positive clinical response to Fasenra therapy
-AND-
(c) Fasenra will be used in combination with maintenance therapy [e.g.,
Advair/AirDuo (fluticasone/salmeterol), Breo Ellipta (fluticasone
furoate/vilanterol), Symbicort (budesonide/ formoterol), Trelegy Ellipta
(fluticasone furoate/umeclidinium/vilanterol)].
-AND-
(d) Patient is not receiving Fasenra in combination with any of the following:
i. Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Nucala
© 2024 UnitedHealthcare Services, Inc.
1
(mepolizumab)]
ii. Anti-IgE therapy [e.g., Xolair (omalizumab)]
iii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
iv. Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g.,
Tezspire (tezepelumab)]
-OR-
(2) All of the following:
(a) Diagnosis of severe asthma
-AND-
(b) Fasenra will be used in combination with maintenance therapy [e.g.,
Advair/AirDuo (fluticasone/salmeterol), Breo Ellipta (fluticasone
furoate/vilanterol), Symbicort (budesonide/ formoterol), Trelegy Ellipta
(fluticasone furoate/umeclidinium/vilanterol)].
-AND-
(c) Asthma is an eosinophilic phenotype
-AND-
(d) Patient is not receiving Fasenra in combination with any of the following:
i. Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Nucala
(mepolizumab)]
ii. Anti-IgE therapy [e.g., Xolair (omalizumab)]
iii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
iv. Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire
(tezepelumab)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Fasenra will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Fasenra therapy
-AND-
(2) Fasenra will be used in combination with maintenance therapy [e.g.,
Advair/AirDuo (fluticasone/salmeterol), Breo Ellipta (fluticasone
furoate/vilanterol), Symbicort (budesonide/ formoterol), Trelegy Ellipta
(fluticasone furoate/umeclidinium/vilanterol)].
-AND-
© 2024 UnitedHealthcare Services, Inc.
2
(3) Patient is not receiving Fasenra in combination with any of the following:
(a) Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Nucala
(mepolizumab)]
(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]
(c) Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
(d) Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire
(tezepelumab)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limitations may be in place.
• Medical Necessity may be in place.
• The prefilled syringe is typically covered under the medical benefit. Please refer to the
United Healthcare Medical Benefit Drug Policy: “Respiratory Interleukins (Cinqair®,
Fasenra®, and Nucala®)”.
4. References:
1. Fasenra [prescribing information]. Wilmington, DE; AstraZeneca Pharmaceuticals LP; April
2024.
Program Prior Authorization/Notification - Fasenra (benralizumab)
Change Control
10/2019 New program.
4/2020 Updated program to address specific product formulations. Updated
references.
4/2021 Annual review. No changes to clinical criteria. Added limitations of
use. Updated references.
11/2021 Added coverage criteria for patients established on therapy under
UnitedHealthcare medical benefit.
11/2022 Annual review with no changes to coverage criteria. Added state
mandate footnote and updated references.
7/2023 Updated required diagnosis to “severe asthma”. Added examples of
maintenance therapy. Added Tezspire to list of agents that should not
be used in combination with Fasenra. Removed bypass of eosinophilic
phenotype requirement for patients currently dependent on maintenance
© 2024 UnitedHealthcare Services, Inc.
3
therapy with oral corticosteroids to align with label.
7/2024 Annual review. Updated background for ages 6 years and older.
Modified criteria for existing prior authorization for under the medical
benefit. Updated reference.
© 2024 UnitedHealthcare Services, Inc.
4